Rautamo, M.; Kvarnström, K.; Sivén, M.; Airaksinen, M.; Lahdenne, P.; Sandler, N.
Benefits and Prerequisites Associated with the Adoption of Oral 3D-Printed Medicines for Pediatric Patients: A Focus Group Study among Healthcare Professionals. Pharmaceutics 2020, 12, 229.
https://doi.org/10.3390/pharmaceutics12030229
AMA Style
Rautamo M, Kvarnström K, Sivén M, Airaksinen M, Lahdenne P, Sandler N.
Benefits and Prerequisites Associated with the Adoption of Oral 3D-Printed Medicines for Pediatric Patients: A Focus Group Study among Healthcare Professionals. Pharmaceutics. 2020; 12(3):229.
https://doi.org/10.3390/pharmaceutics12030229
Chicago/Turabian Style
Rautamo, Maria, Kirsi Kvarnström, Mia Sivén, Marja Airaksinen, Pekka Lahdenne, and Niklas Sandler.
2020. "Benefits and Prerequisites Associated with the Adoption of Oral 3D-Printed Medicines for Pediatric Patients: A Focus Group Study among Healthcare Professionals" Pharmaceutics 12, no. 3: 229.
https://doi.org/10.3390/pharmaceutics12030229
APA Style
Rautamo, M., Kvarnström, K., Sivén, M., Airaksinen, M., Lahdenne, P., & Sandler, N.
(2020). Benefits and Prerequisites Associated with the Adoption of Oral 3D-Printed Medicines for Pediatric Patients: A Focus Group Study among Healthcare Professionals. Pharmaceutics, 12(3), 229.
https://doi.org/10.3390/pharmaceutics12030229
